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Abstract
Purpose Pure ureter cancers are rare and account for only
1–3 % of urothelial carcinomas with limited data. Nowa-
days, nephron-sparing methods are reserved mainly for
imperative cases. This study intends to assess the oncologic
outcome between segmental ureterectomy (SU) and radical
nephroureterectomy (RNU) for pure ureteral urothelial
carcinoma.
Methods From July 2004 to August 2010, 112 patients at
a single tertiary referral center were included. Perioperative
data were obtained from our institutional database. Post-
operative CT scan, cystoscopy, and contralateral renal echo
were performed regularly for survey of disease recurrence.
Results The mean length of follow-up was 43.8 and
48.3 months for the RNU and SU group, respectively. The
bladder recurrences, local recurrences, distant metastasis,
and cancer-specific survival rates showed no significant
differences between RNU and SU (36.4 vs. 34.2 %,
p = 0.83; 23.4 vs. 14.3 %, p = 0.27; and 16.9 vs. 8.6 %,
p = 0.244, and 13.0 vs. 5.7 %, p = 0.249, respectively).
Conclusion The study suggested that SU is not inferior to
RNU for ureter cancer in oncologic outcomes and is less
invasive and better nephron preservation.
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Upper urinary tract urothelial carcinomas (UUT-UC),
especially pure ureter cancers, are rare and account for only
1–3 % of urothelial carcinomas [1], and limited data about
pure ureter cancers have been reported. Although the
concept for preservation of renal function has been
emphasized nowadays, radical nephroureterectomy with
excision of the bladder cuff (RNU) remains the gold
standard treatment for upper urinary tract urothelial carci-
nomas (UUT-UCs) [2]. Nephron-sparing methods such as
endoscopic ablation or segmental ureterectomy (SU) are
reserved for imperative cases such as renal insufficiency,
solitary functional kidney, low-grade, and low-stage
tumors [3–5]. Recent studies supporting oncologic out-
comes of SU were comparable to RNU in select cases [4, 6,
8]. This study intends to assess the oncologic outcome
between SU and RNU in patients with ureter urothelial
cancer treated at a single tertiary referral center.
Materials and methods
From July 2004 to August 2010, 112 patients with pure
ureter cancer were included in this study. All patients
received CT scan and cystoscopy for diagnosis of distant
metastasis or concurrent bladder tumor; 77 patients
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underwent RNU and 35 patients underwent SU (Table 1).
Segmental ureterectomy was performed under good pro-
tection of surrounding tissue to prevent local seeding of
urothelial tumors. Radical nephroureterectomy was per-
formed along with standard en bloc bladder cuff excision.
Perioperative data were obtained from our institutional
database. SU was indicated in cases as patients with
chronic renal insufficiency, solitary kidney, and patients’
request. There were no statistically significant differences
between age, gender, smoking, tumor grade, preoperative
eGFR, advanced pathology (stage more than T2 or positive
lymphovascular invasion), and bladder cancer histories.
Postoperative CT scan, cystoscopy, and contralateral renal
echo were performed regularly for survey of disease
recurrence. None of these patients received adjuvant che-
motherapy or radiotherapy. The postoperative eGFR mea-
sured at 1 year after surgery. When comparing the
perioperative eGFR change, we excluded patients with
end-stage renal disease. Software SPSS version 17 was
used for statistical analysis in this study. Chi-square and
two-sample t test were used for intergroup comparison,
while Kaplan–Meier survival plot was used for comparison
of recurrence-free survival or cancer-specific survival.
Statistical significance was set if p value was \0.05.
Results
The patients were mainly elderly in this study with median
age being 68 years old. The mean length of follow-up was
43.8 and 48.3 months for the RNU and SU group,
respectively (p = 0.344) (Table 1). There were 17 patients
in the RNU group had multifocality, and 2 patients in the
SU group had multifocal lesions (p = 0.032). Both groups
has similar ratio of patient with bladder cancer history,
21 % in RNU group and 23 % in SU group (p = 0.804).
The bladder recurrences rates, local recurrences rates,
distant metastasis rates in univariate analysis showed no
significant differences between RNU and SU (36.4 vs.
34.2 %, p = 0.83; 23.4 vs. 14.3 %, p = 0.27; and 16.9 vs.
8.6 %, p = 0.244, respectively). No significant differences
existed between surgical intervention with regard to
cumulative bladder recurrence-free survival (Fig. 1,
p = 0.865); local recurrence-free survival (Fig. 2, p =
0.302); distant metastasis-free survival (Fig. 3, p = 0.219),
and cancer-specific survival (Fig. 4, p = 0.212). The
postoperative eGFR improved 1.19 ± 14.94 ml/min/
1.73 m2 in SU group, and the postoperative eGFR
decreased 10.66 ± 24.49 ml/min/1.73 m2 in RNU group.
The RNU group had worse eGFR after operation than SU
group (p = 0.011). There were higher local recurrence rate
in multifocal lesions patients (p = 0.047, HR 3.9, 95 % CI
1.1–14.8). When divided the patients into advanced stage
([T2) and non-advanced stage (^T2) in multivariate
analysis, there were higher local recurrences (p \ 0.001.
HR 9.4, 95 % CI 2.8–31.8), distant metastasis (p = 0.002,
HR 11.2, 95 % CI 2.5–50.8), and cancer-specific survival
rates (p = 0.07, HR 8.8, 95 % CI 1.8–43.2) in advanced
stage patients. Patients with bladder cancer histories had
higher bladder recurrence rate (p = 0.025, HR 3.2, 95 %
CI 1.2–8.6). Otherwise, smoking patients had more bladder
recurrence (p = 0.033, HR 3.7, 95 % CI 1.1–11.9) and
distance metastasis (p = 0.012, HR 6.2, 95 % CI 1.5–25.6)
(Tables 2, 3).
Table 1 Patient characteristics
RNU SU p value
Patient number 77 35
Follow-up duration
(months)
43.84 ± 20.64 48.26 ± 26.97 0.344
Age 66.71 ± 9.96 69.29 ± 9.44 0.201
Male/female 41/36 18/17 0.858
High grade 68 (88.3 %) 30 (85.7 %) 0.700
Multifocality 17 (22 %) 2 (5.7 %) 0.032
Preoperative eGFR 54.60 ± 28.78 56.31 ± 33.62 0.522
Postoperative eGFR
change
-10.66 ± 24.5 1.18 ± 14.9 0.011
Bladder cancer history 16 (20.8 %) 8 (22.9 %) 0.804
Non-organ confined
([T2)
15 (19.5 %) 11 (31.4 %) 0.165
Bladder recurrence 28 (36.4 %) 12 (34.2 %) 0.832
Local recurrence 18 (23.4 %) 5 (14.3 %) 0.270
Distant metastasis 13 (16.9 %) 3 (8.6 %) 0.244
Cancer death 10 (13.0 %) 2 (5.7 %) 0.249
Fig. 1 Bladder recurrence free survival
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Discussion
Upper urinary tract cancer, especially pure ureter cancer, is
a rare malignancy. RNU with bladder cuff removal remains
the gold standard treatment for ureter cancer [2]. However,
according to the reviewed literature, patients with UUT-UC
having high prevalence of chronic kidney disease and renal
function often deteriorated after RNU [9, 10]. Ou et al. [11]
hypothesized that the uremic environment may be a sig-
nificant factor promoting the underlying urinary tract dis-
ease to develop cancers. To preserve renal function,
nephron-sparing methods such as endoscopic ureter tumor
excision and SU were developed, which are alternative
choices of treatment for imperative indication [5, 12]. More
and more series have indicated the important role of
nephron-sparing methods for ureter cancer patients even
with contralateral normal kidney or locally advanced
pathological features [4, 9, 13]. Further validation about the
safety of SU is worthy of investigation.
Nephron-sparing surgeries for ureter cancer such as
endoscopic ureter tumor excision and SU have been
reported to have acceptable oncologic outcome. Endo-
scopic ureter tumor excision has even been reported to
manage early stage and superficial tumor, but the under-
staging and increased risk of recurrences were noted [14].
However, even for muscle invasive ureter cancer, SU could
possibly achieve en bloc resection of the ureter tumor with
surrounding tissue. Preoperative diagnosis of muscle
invasive ureter cancer is the key point to decide whether
endoscopic or segmental ureterectomy should be safely
performed. Several series have attempted to develop no-
mograms based on preoperative imaging, tumor grade from
ureteroscopic biopsy, architecture, and location for the
prediction of non-organ-confined UUT-UC [15, 16]. It is
still difficult to differentiate between muscle invasive and
non-muscle invasive diseases preoperatively. SU seems to
be more suited to ureter tumor excision without the risk of
ureter perforation by endoscopic excision and thus has
routinely been performed in our institution for patients
willing to preserve the kidneys. Considering the bias from
the open or endoscopic approach and different surgical
techniques by surgeons, this study only assessed the on-
cologic outcome of SU compared with RNU by a single
tertiary center experience.
Fig. 2 Local recurrence free survival
Fig. 3 Distance metastasis free survival Fig. 4 Cancer specific survival
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NCCN guidelines for upper urinary tract cancer suggest
standard nephroureterectomy with bladder cuff excision for
high-grade mid-ureter cancer and all upper ureter cancer
[7]. Distal ureterectomy with ureter reimplantation could
be considered for clinically feasible patients. However,
Colin et al. reported a multicenter cohort study of ureter
cancer which suggested that tumor location and surgical
interventions were not an independent prognostic factor for
recurrence-free survival or cancer-specific mortality [8]. In
addition, the 5-year probability of CSS, RFS, and MFS for
SU and RNU were 87.9 and 86.3 % (p = 0.99); 37 and
47.9 % (p = 0.48); and 81.9 and 85.4 % (p = 0.51),
respectively. Jeldres et al. also reported the oncologic
outcome among SU, RUN with bladder cuff removal, and
RNU without bladder cuff removal. The 5-year cancer-
specific mortality-free rates were 86.6 versus 82.2 versus
80.5 %, respectively, without significant differences. The
populations of these studies were relatively unequal in
patient numbers because of the retrospective design. These
results are similar to our observations. Our result revealed
that advanced pathology of ureter cancer is common,
occupying 19.5 and 31.4 % in RNU and SU groups,
respectively. However, cancer-specific survival was similar
between SU and RNU in both non-advanced and advanced
pathology of pure ureter cancer patients in our study.
Kaplan–Meier plot also revealed that SU did not increase
the disease recurrences compared with RNU.
Although in the study, we noted that pathological stage
is still the most important predictor for local and distant
oncologic failure with subsequent cancer-specific death.
Table 2 Multivariate analysis for bladder and local recurrence
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HR 3.2, 95 % CI 1.2–8.6
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Table 3 Multivariate analysis for distant metastasis and cancer death
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The evidence we reviewed support that SU is not inferior to
RNU even for locally advanced ureter cancer, which is at
high risk for adjuvant chemotherapy. Despite adequate
radical surgery, disease recurrence is not uncommon for
UUT-UC. For distant metastasis or unrespectable disease,
cisplatin-based chemotherapy is now the current treatment
of choice. The advantage of SU is kidney preservation with
better renal function outcome and then increased eligibility
for adjuvant chemotherapy [12]. In our study, not only the
RNU group had significant eGFR decrease, but also the SU
group showed improvement in renal function. Jonathan L.
et al also mentioned about this phenomenon may contribute
to the resection of a ureteral tumor with obstructive urop-
athy [17]. In addition, CKD is well known to cause more
cardiovascular disease and subsequent mortality [18]. The
actual benefit of SU upon CKD prevention for patients with
ureter cancer and its correlation between cancer-specific or
overall survival benefit is worthy of further investigation.
Through multivariate analysis, we reveled that urinary
bladder cancer historied are independently associated with
urinary bladder tumor recurrence. And also smoking is a
related factor to urinary bladder recurrence and distant
recurrence. Maurice et al. [19] reported approximately
threefold higher risk of urinary tract cancer in cigarette
smokers than non-smokers.
The limitations of this study are its retrospective, non-
randomized design, and relatively small sample size. There
were unequal case numbers for multifocal tumor, and it is
reasonable because that multifocal tumor is not always
suitable for nephron-sparing method. Thus, we used multi-
variate analysis to identify the impact of cancer control. Most
of our multifocal cases received SU because of chronic renal
insufficiency or multiple comorbidity so that patients deci-
ded to have nephron-sparing surgery and our data supported
that there was no significant difference in bladder recurrence,
distant recurrence, or cancer-specific survival.
However, the advantage is single tertiary center expe-
riences without bias from patient population and basic
surgical procedures; especially in Southern Taiwan, we
have a higher prevalence of upper urinary tract cancers in
black foot endemic areas [20]. We present the result with
detailed pathology review and patient follow-up. The
intention is to help validate the role of SU in treating
patients with ureter urothelial cancer.
Conclusion
The study suggested that SU is not inferior to RNU for
ureter cancer in oncologic outcome. In addition, SU is less
invasive and has better nephron preservation compared
with RNU. Further randomized studies with larger cohort
series are still necessary to support the results.
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